Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2521 to 2535 of 2854 results for process

  1. Rheumatoid arthritis in adults: management (NG100)

    This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.

  2. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

  3. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    Discontinued Reference number: GID-TA10568

  4. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

  5. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

  6. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

  7. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued Reference number: GID-TA10413

  8. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

  9. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    Discontinued Reference number: GID-TA11569

  10. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

  11. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

  12. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

  13. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

    This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.

  14. Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.